These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 1509995)

  • 1. Flecainide in the Wolff-Parkinson-White syndrome.
    Crozier I
    Am J Cardiol; 1992 Aug; 70(5):26A-32A. PubMed ID: 1509995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of oral and injectable flecainide in patients with an accessory atrioventricular pathway].
    Fauchier JP; Cosnay P; Rouesnel P; Moquet B; Bonnet P; Scala PJ; Demeyer JF
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():81-90. PubMed ID: 3938264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blocker therapy for the Wolff-Parkinson-White syndrome.
    Prystowsky EN; Greer S; Packer DL; Thompson KA; German LD
    Am J Cardiol; 1987 Aug; 60(6):46D-50D. PubMed ID: 2888300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome.
    Kappenberger LJ; Fromer MA; Shenasa M; Gloor HO
    Clin Cardiol; 1985 Jun; 8(6):321-6. PubMed ID: 4006340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
    O'Nunain S; Garratt CJ; Linker NJ; Gill J; Ward DE; Camm AJ
    Pacing Clin Electrophysiol; 1991 Nov; 14(11 Pt 2):2028-34. PubMed ID: 1721219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Electrophysiologic properties of cibenzoline in Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia].
    Kühlkamp V; Ickrath O; Schmid F; Mayer F; Haasis R; Seipel L
    Z Kardiol; 1989 Oct; 78(10):640-6. PubMed ID: 2686251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of flecainide for supraventricular tachycardia.
    Neuss H; Schlepper M
    Am J Cardiol; 1988 Aug; 62(6):56D-61D. PubMed ID: 3136637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
    Ludmer PL; McGowan NE; Antman EM; Friedman PL
    J Am Coll Cardiol; 1987 Jun; 9(6):1357-63. PubMed ID: 3294970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome.
    Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T
    Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Administration of adenosine for termination of atrioventricular nodal reentry tachycardia: induction of atrial fibrillation with rapid conduction over an accessory pathway and unmasking of concomitant Wolff-Parkinson-White syndrome].
    Drescher S; Bosch RF; Mewis C; Kühlkamp V
    Z Kardiol; 2000 Jun; 89(6):522-6. PubMed ID: 10929437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome.
    Neuss H; Buss J; Schlepper M; Berthold R; Mitrović V; Krämer A; Musial WJ
    Eur Heart J; 1983 May; 4(5):347-53. PubMed ID: 6617681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
    Kanemoto M; Shimizu A; Yamagata T; Esato M; Ueyama T; Yoshiga Y; Kakugawa H; Kametani R; Inoue N; Sawa A; Matsuzaki M
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):295-303. PubMed ID: 15367827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia.
    Jackman WM; Friday KJ; Fitzgerald DM; Yeung-Lai-Wah JA; Lazzara R
    Am J Cardiol; 1988 Dec; 62(19):8L-19L. PubMed ID: 3059792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic effects of isoproterenol in patients with atrioventricular reentrant tachycardia treated with flecainide.
    Helmy I; Scheinman MM; Herre JM; Sharkey H; Griffin JC
    J Am Coll Cardiol; 1990 Dec; 16(7):1649-55. PubMed ID: 2123908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Oct; 31(10):1227-43. PubMed ID: 9337449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of efficacy of flecainide in the Wolff-Parkinson-White syndrome after isoproterenol administration.
    Brembilla-Perrot B; Admant P; Le Helloco A; Pernot C
    Eur Heart J; 1985 Dec; 6(12):1074-8. PubMed ID: 3830711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias.
    Hohnloser SH; Zabel M
    Am J Cardiol; 1992 Aug; 70(5):3A-9A; discussion 9A-10A. PubMed ID: 1387287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome.
    Camm AJ; Katritsis D; Nunain SO
    Am J Cardiol; 1992 Aug; 70(5):33A-37A. PubMed ID: 1509996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias.
    Wiseman MN; Elstob JE; Camm AJ; Nathan AW
    Pacing Clin Electrophysiol; 1990 Jun; 13(6):767-75. PubMed ID: 1695357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological action of bepridil on atrioventricular accessory pathways.
    Touboul P; Atallah G; Kirkorian G; Lavaud P; Kieny JR; Mathieu MP; Dellinger A
    Br Heart J; 1987 Oct; 58(4):333-8. PubMed ID: 3499924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.